Για να δείτε αναλυτικά τα περιεχόμενα του βιβλίου ή να το παραγγείλετε πατήστε εδώ…

Novo Nordisk Establishes Type 1 Diabetes R&D Center

PRINCETON, N.J., Jan. 23, 2012 /PRNewswire/ -- Novo Nordisk (NYSE:NVO) announced today that the company will establish a type 1 diabetes research and development center in Seattle, Wash., U.S. The new center will combine Novo Nordisk's history of innovation and leadership in diabetes treatment with the company's growing expertise in immunotherapy.

"Novo Nordisk has been passionate about helping people fight diabetes since the company was founded, and it is part of our mission to take type 1 diabetes research to the next level," said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. "With the new type 1 diabetes R&D center, we hope to accelerate the process of finding new, innovative ways of treating people with this disease. Our vision is to prevent, treat and ultimately cure diabetes."

European Coronary Stent Market to Decline to $490 Million by 2016, Despite Growth in Number of Procedures

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, while the number of coronary stenting procedures performed will show steady growth, stent selling prices will decline significantly, resulting in a decline in overall market value that will average 3.5 percent per year through 2016. One exception to the overall market decline will be drug-eluting bioresorbable scaffolds and biodegradable polymer drug eluting stents (DES), which are expected to be adopted over this period and limit the slide in market value.

Recent innovations in DES stents show promise. Biodegradable polymer drug-eluting stents, for example, offer a better safety profile than durable-polymer drug-eluting stents, as late-stent thrombosis is largely attributed to the polymer that binds the drug to the stent. In biodegradable polymer stents, a polymer controls drug release but then disappears, leaving a bare metal stent. Examples of stents with biodegradable polymers are Biosensors International's BioMatrix, Terumo Medical's Nobori, Sahajanand Medical Technologies' Supralimus and Boston Scientific's fourth generation Synergy stent, which is still in development.

Study Questions Efficacy of Online Patient Health Portals

Only about one-quarter of patients who were given access to an online portal containing information about colorectal cancer screening actually used the site, according to a study published this month in the Journal of Health Communication, FierceHealthIT reports.

Study Details

The study consisted of 130 women mainly between ages 50 and 59 who were considered to be at an average risk for colorectal cancer.
Eighty-three percent of the participants said they spent an average of one hour per day on the Internet.

Social media marketing helps healthcare companies boost customer service

A report from eMarketer found that healthcare companies are working to improve their image through social media marketing.

In an interview with eMarketer, Maureen Maldari, president for Grey Healthy People, said that social media marketing campaigns have changed the way some healthcare companies operate. The organizations say using the channel to develop customer relationships proves financially beneficial and makes it easy to provide health resources to patients.

Who complains about pharmaceutical side effects online?

It's one of a pharma PR rep's worst nightmares: Somebody complains online that the medicine they are taking is causing unpleasant side effects.

Because of the fear of people complaining about their product on social media sites, pharma companies can be reluctant to join in the social media conversation. But how many people are really reporting adverse events from medication?

During a 30-day period, Visible Technologies tracked 224 pharmaceutical brands and analyzed more than 257,000 posts from various social media sites to analyze the frequency of adverse event reporting. The number of adverse events reported was surprisingly low.

Στάση εργασίας των φαρμακοποιών σήμερα το απόγευμα

Την κήρυξη στάσης εργασίας των φαρμακείων σήμερα Τρίτη 24/1/2012 στις ώρες του απογευματινού ωραίου στην διάρκεια της συζήτησης στην Βουλή, της τροπολογίας την «απελευθέρωση» του ωραρίου των φαρμακείων αποφάσισε ο Πανελλήνιος Φαρμακευτικός Σύλλογος.

Όπως αναφέρει ο Σύλλογος στη σχετική του ανακοίνωση, με την τροπολογία αυτή παρακάμπτεται κάθε έννοια ασφάλειας στην χορήγηση των φαρμάκων από κουρασμένους φαρμακοποιούς, δεν υφίσταται ωράριο λειτουργίας ούτε και πίνακες διημερεύσεων και διανυκτερεύσεων.
Υποστηρίζει ακόμη πως η τροπολογία αυτή έρχεται σε αντίθεση ακόμα και με το Ευρωπαϊκό Δίκαιο.

Για να δείτε αναλυτικά τα περιεχόμενα του βιβλίου ή να το παραγγείλετε πατήστε εδώ…

Fitch: Pharmaceutical Industry Could Use a Shot in the Arm

Fitch Ratings says 2012 will be a critical year for the pharmaceutical industry, as drug makers struggle with record patent expirations, disappointing results of expensive clinical trials, and ongoing regulatory challenges against an already challenging economic backdrop.

Large pharmaceutical companies remain pressured and some are bracing themselves for a steep drop off the patent cliff. We believe the loss of patent exclusivity on blockbuster drugs will continue to spur increasing competitive pressure as generic versions of branded medications hit the market. We note that more than $70 billion of branded drug revenues (based on 2010 sales) will lose or have already lost patent protection from the second half 2011 to the end of 2015.

Φαρμακοποιοί προς Ανδρέα Λοβέρδο

 
19 Ιανουαρίου 2012

Προς Υπουργό Υγείας κ. Α. Λοβέρδο
 
Κύριε Υπουργέ,                                                                                                                  Αφήσαμε να περάσουν κάποιες μέρες από τις δηλώσεις σας στον τηλεοπτικό σταθμό Αντένα, σχετικά με την κινητοποίησή μας, που όπως ισχυριστήκατε είχε ως αποτέλεσμα την μεγάλη ταλαιπωρία των ασφαλισμένων. Αυτό το κάναμε για να δώσουμε χρόνο στους εαυτούς μας να συνειδητοποιήσουν αυτά που είπατε και να αντιδράσουν με νηφαλιότητα και όχι εν θερμώ.

Στην εκπομπή αυτή αναφερθήκατε επίσης και σε μελλοντικές πιθανές κινητοποιήσεις του κλάδου, καλώντας τον Πρόεδρο του Πανελληνίου Φαρμακευτικού Συλλόγου να υπογράψει μαζί σας συμφωνητικό «περί μη μελλοντικής ταλαιπωρίας των ασφαλισμένων», απειλώντας μάλιστα ότι σε ενδεχόμενη νέα κινητοποίηση θα εφαρμόζατε το σύστημα των ατομικών συμβάσεων.
Κατανοούμε λοιπόν, ότι όλα τα ανωτέρω τα είπατε είτε επειδή δεν είχατε άμεση πληροφόρηση των γεγονότων, είτε επειδή θέλατε να εντυπωσιάσετε. Σε κάθε περίπτωση, όπως θα σας αποδείξουμε κατωτέρω, έχετε κάνει σε όλα λάθος.